Xcout Intel
Keros
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Subscribe to see Keros’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Keros at a glance
Keros is a biotech company headquartered in United States. Its most recent funding round, Series C, raised $56M in March 2020. Xcout tracks 11 named people at Keros, including Jasbir Seehra, Ph.D. (President, Chief Executive Officer and Director). Xcout recorded 46 job postings from Keros in the last 90 days, naming tools such as SAP.
Keros leadership
- Jasbir Seehra, Ph.D.President, Chief Executive Officer and Director
- Esther Cho, J.D.Chief Legal Officer
- Lorena Lerner, Ph.D.Chief Scientific Officer
- Annita Tanini, M.B.A.Corporate Controller and Vice President, Finance
- Jean-Jacques Bienaimé, M.B.A.Chairman
- Alpna Seth, Ph.D.Member of our board of directors
5 more named people on record for Keros, with roles, board committees and tenure — see the full roster →
Keros funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $56M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Keros
Xcout recorded 46 job postings from Keros in the last 90 days, from a hiring record Xcout has kept since July 2026.
Tools named in Keros's job postings
The weekly hiring trend, the roles and locations behind it — see Keros's hiring signals →
Investors
Tech stack
Keros competitors
A few of Keros's closest competitors — see the full list of competitors and alternatives →
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Ikaika Therapeutics is a biotechnology company developing first-in-class anti-fibrotic biologic therapies for patients with fibrotic diseases, including muscular dystrophy. The company's lead technology utilizes antibodies, such as IKN-001, to inhibit the activation of transforming growth factor-beta (TGF-beta) by protecting latent TGF-beta binding protein 4 (LTBP4) from protease cleavage.
Akero Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is dedicated to developing transformational therapies for metabolic dysfunction-associated steatohepatitis and other metabolic diseases.
Fulcrum Therapeutics is a biotechnology company developing new medicines aimed at transforming gene regulation to deliver treatments to patients and their families.
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases.
Mariposa Therapeutics Ltd is a biotechnology company founded in 2019 and headquartered in Cardiff, United Kingdom. The company is dedicated to researching and developing innovative therapeutic solutions for keratin-related disorders. Its scientific efforts are supported by specialized research investments aimed at addressing rare skin and tissue conditions.
Get Keros's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Keros? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Keros in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access